Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pruritus is a frequent symptom in medicine. Population-based studies show that one in five persons in the general population has suffered from chronic pruritus (CP) at least once in their lifetime, with a 12-month incidence of 7%. CP, which can affect all age groups, is associated with numerous, often interdisciplinary medical conditions. It needs a precise diagnostic work-up to identify causes and relevant comorbidities. Management of CP comprises treatment of the underlying disease as well as topical and systemic therapies. Treating CP needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. In recent years, novel on-label therapies have been approved for CP, including therapies for chronic prurigo and cholestatic pruritus. We present the updated European guideline on chronic pruritus by a team of European pruritus experts from different disciplines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/actadv.v105.44220 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting PAR-2 in atopic dermatitis: Preclinical evaluation of the novel inhibitor E6795.
Biochem Biophys Res Commun
September 2025
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan; A∗STAR Skin Research Labs (A∗SRL), Skin Research Institute of Singapore (SRIS), Singapore Immunology Network (SIgN), Agency for Science, Technology, and Research (A∗STAR), 8A Biomedical Grove, IMMUNOS Buildi
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous lesions, intense itching, and compromised skin barrier function. Despite the advent of new therapeutics, many individuals still face insufficient disease control, high costs, and relapse. Protease-activated receptor 2 (PAR-2), overexpressed in AD lesions, plays a central role in promoting inflammation, itch, and alterations in epidermal homeostasis.
View Article and Find Full Text PDFRocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.
Dermatol Ther (Heidelb)
September 2025
Department of Dermatology, Kyoto University, Kyoto, Japan.
Atopic dermatitis (AD) is a chronic inflammatory disease characterized by eczematous skin lesions, intense pruritus, skin pain, sleep disruption, and mental health disturbances. There remains a need for a therapeutic option that delivers durable efficacy, safety, and convenient dosing across the AD patient population. This review provides an overview of AD pathogenesis driven by T-cell imbalance and describes a novel therapeutic option targeting the OX40 receptor, a costimulatory molecule expressed specifically on activated T cells.
View Article and Find Full Text PDFBackground: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by complex interactions among Staphylococcus aureus colonization and immunologic, genetic, and environmental (SAIGE) triggers. Currently, no single therapy comprehensively addresses all triggers and the full spectrum of AD manifestations, highlighting an unmet need for therapies that simultaneously target all components of the disease continuum.
Methods: An expert panel conducted a structured literature review and developed consensus statements during a meeting in March 2025.
Atopic dermatitis, hypertension, and cardiovascular risk: an appraisal of the evidence.
Ital J Dermatol Venerol
September 2025
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Atopic dermatitis is the most common chronically or chronically relapsing inflammatory skin disease, characterized by intense pruritus, eczematous lesions, and a significant disease burden. Emerging evidence in recent years suggests that atopic dermatitis and the associated chronic systemic inflammation have health implications beyond the skin. For psoriasis, another chronic inflammatory skin disease, the association with cardiovascular diseases (CVDs) is well-established.
View Article and Find Full Text PDFEffects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh.
Cureus
August 2025
Department of Medicine, Bangladesh Institute of Health Sciences (BIHS) General Hospital, Dhaka, BGD.
Objective: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder frequently associated with obesity, leading to increased risks of cardiovascular and renal complications. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a promising therapeutic agent for improving glycemic control and promoting weight reduction. However, evaluating its safety and efficacy in obese T2DM patients remains essential, particularly in real-world clinical settings.
View Article and Find Full Text PDF